- Avalon GloboCare (AVCO -3.9%) announces that it has entered into a collaboration agreement with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center to advance the clinical development and production of Avalon’s next-generation, chimeric antigen receptor (CAR) therapies using FLASH CAR technology.
- The FLASH-CAR technology modifies patients’ T-cells and natural killer (NK) cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, and is being co-developed with the Company’s strategic partner, Arbele Limited.
- Under the agreement, Avalon and the UPMC Hillman Cancer Center will co-develop and deploy the company's new Point-of-Care Modular Autonomous Processing System ((PMAPsys)) onsite at the UPMC Hillman Cancer Center, a National Cancer Institute (NCI)-designated comprehensive cancer center in the United States.
- The company also highlighted that its First FLASH-CAR candidate, AVA-011, is on-track for clinical study in B-cell lymphoblastic leukemia and non-Hodgkin’s lymphoma patients.